We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » US Radioactive Drug Guidance Draws Line Between Basic Human, Clinical Research
US Radioactive Drug Guidance Draws Line Between Basic Human, Clinical Research
August 16, 2010
Sponsors of radioactive drugs or biologics do not need an investigational new drug (IND) approval to conduct basic human research in the U.S., but such studies do require approval from a Radioactive Drug Research Committee (RDRC), according to a final guidance.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor